Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY)

Market Cap	55.72B +39.8%
Revenue (ttm)	4.52B +13.0%
Net Income	1.10B +21.7%
EPS	0.17 +18.0%
Shares Out	n/a
PE Ratio	50.54
Forward PE	40.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226
Average Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	16.72 - 16.72
Beta	n/a
RSI	n/a
Earnings Date	Mar 25, 2026

About JHPCY

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 20,602
• Stock Exchange: OTCMKTS
• Ticker Symbol: JHPCY

Financial Performance

In 2025, JHPCY's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY